Category: CBDiary

W.H.O. says nix on Carfentanil, ‘Later’ for CBD

From the World Health Organization, 13 DECEMBER 2017 – WHO has this week endorsed a recommendation from the Expert Committee on Drug Dependence (ECDD) to include carfentanil, an analogue of the prescription opioid fentanyl, into Schedules I and IV of the 1961 UN Single Convention on Narcotic Drugs. Schedule I substances are subject to strict drug control measures. Additional control under Schedule IV imposes the strongest possible regulations on substances by prohibiting production and supply of substances except under licence for specific purposes, such as medical treatment and research. In the case of carfentanil, there is no indication for...

Read More

Cannabinoids for prevention of migraines

A study presented at the Congress of the European Academy of Neurology in Amsterdam confirmed that cannabinoids are just as suitable as a prophylaxis for migraine attacks as other pharmaceutical treatments. Interestingly though, when it comes to treating acute cluster headaches they are only effective in patients that suffered from migraine in childhood. Amsterdam, 24 June 2017 – Germany’s recent decision to liberalise the use of cannabis for medical purposes has rekindled policy debate across Europe. While politics and health authorities continue to weigh up the pros and cons of this treatment method, researchers are constantly furthering scientific understanding...

Read More

Safety of CBD —A Review of the Literature

Safety and Side Effects of Cannabidiol– A review of clinical data and relevant animal studies by Kerstin If and (B.Sc. Biomedicine, M.Sc. Neuroscience) and Dr. med. Franjo Grotenhermen, nova-Institut (www.nova-institut.eu) Hürth (Germany), October 2016 Abstract This literature survey aims to provide an update of the extensive survey performed by Bergamaschi and colleagues in 2011. Apart from updating the literature, this paper focuses on clinical studies and CBD’s potential interactions with other drugs. In general, the often described excellent safety profile of CBD in humans was confirmed and extended by the reviewed research. The majority of studies were performed for...

Read More

The City Council Considers Cannabis

It was standing room only September 5 as the City Council held a “workshop” on the prospect of the cannabis industry coming to Alameda. The council intends to come up with an ordinance regulating commercial production and distribution before January 1, 2018, when California’s “legalization” laws kick in. City staff had paid the SCI Consultancy Group $60,000 to draft an ordinance for the city council to customize. Neil Hall of SCI provided a 20-minute power point presentation on the history of the industry and the relevant laws. Community Development Director Debbie Potter  reported that staff had done a “randomized”...

Read More

When the Village Voice Broke the Medical MJ Story

Another outlet done gone for your correspondent. The Village Voice has folded as a print publication. Some of my friends wrote for them regularly —Paul Cowan, Bob Christgau, Sally Kempton, Alex Cockburn, Jack Newfield— and I did occasionally. In 1978 I helped break the Paraquat story in The Voice. In 1996 they ran a cut version of a piece about Prop 215, California’s medical marijuana initiative, that I’d been assigned by The New Yorker.  “If it passes,” I wrote on the eve of the vote, “the drug war as we have known it will end. California will become a demilitarized zone in...

Read More